Altre lingue Xspray Pharma AB

Azioni

XSPRAY

SE0009973563

Mercato chiuso - Nasdaq Stockholm Altri mercati azionari 18:00:00 09/07/2024			Variaz. 5gg	Var. 1 gen.
78,1 ^SEK	-1,76%		-2,13%	+95,25%

09/07	Lo studio Xs003 di Xspray Pharma Ab mostra una biodisponibilità pari a quella di Tasigna con una dose inferiore di oltre il 50%.	CI
23/05	Xspray Pharma AB (publ) annuncia di presentare i dati all'ASCO, evidenziando la frequente commisurazione degli IPP con i TKI nei pazienti affetti da CML e gli effetti positivi maggiori del previsto sulla biodisponibilità di Dasatinib cristallino.	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Xspray Pharma’s XS003 Study Shows Matching Bioavailability to Tasigna at More than a 50% Lower Dose	09/07
Xspray Pharma Ab's Xs003 Study Shows Matching Bioavailability to Tasigna At More Than A 50% Lower Dose	09/07
Xspray Pharma : XS003 Study shows Matching Bioavailability to Tasigna at more than a 50% Lower Dose	09/07
Xspray Pharma’s XS003 Study shows Matching Bioavailability to Tasigna at more than a 50% Lower Dose	09/07
New number of shares and votes in Xspray Pharma after TO6	31/05
Xspray to present data at ASCO highlighting frequent comedication of PPIs with TKIs in CML-patients and greater than expected negative effects on the bioavailability of crystalline dasatinib	23/05
Xspray Pharma AB Announces to Present Data At ASCO Highlighting Frequent Decideication of PPIs with TKIs in CML-Patients and Greater Than Expected Positive Effects on the Bioavailability of Crystalline Dasatinib	23/05
Bulletin from the annual general meeting of Xspray Pharma AB (publ), 21 May 2024	21/05
Xspray Pharma appoints Chief Operating Officer and changes the Management Team	20/05
Xspray Pharma AB Appoints Linda Glimberg as Chief Operating Officer, Effective June 1, 2024	20/05
Xspray Pharma AB Appoints Niklas Adenborg as Chief Financial Officer, Effective July 1, 2024	20/05
Xspray Pharma Q1 2024 - Reveal of XS025 and PDUFA is nearing	13/05
Interim Report First Quarter 2024	08/05
Xspray Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
Xspray Pharma raises SEK 100.3 million through warrants TO6	03/05
Xspray Pharma Announces Fourth Product Candidate, targeting USD 2.3 billion Market	22/04
Xspray Pharma Announces Fourth Product Candidate, Targeting USD 2.3 Billion Market	22/04
Xspray Pharma receives declaration of intent from Östersjöstiftelsen regarding exercise of TO6 warrants	19/04
Important information to holders of warrants series TO6: subscription period begins today	18/04
Notice of annual general meeting of Xspray Pharma AB (publ)	18/04

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Xspray Pharma AB

Azioni

XSPRAY

SE0009973563

Altre lingue

Filtri